2006 Fiscal Year Final Research Report Summary
Development of immune therapy against primary biliary cirrhosis using tolerogenic dendritic cells
| Project/Area Number |
17590651
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Ehime University |
|---|
Principal Investigator |
AKBAR S.M.F. Ehime University, Graduate School of Medicine, Lecturer, 大学院・医学系研究科, 講師 (90294793)
|
|---|
| Project Period (FY) |
2005 – 2006
|
| Keywords | Primary biliary cirrhosis / Regulatory dendritic cells / Poly I : C / Interleukin-10 / Bone marrow DC |
|---|
| Research Abstract |
Antigen-presenting dendritic cells (DCs) are regulator of immunity and they can induce both immunogenecity and tolerogenecity. Inmunogenic dendritic cells (DCs) have been used for last one decades for treatment of cancers. On the contrary, tolerogenic DCs can be used for treatment of autoimmune diseases, however few trials have been conducted in this regard.. In this study, we prepared tolerogenic DCs in vitro by culturing murine bone marrow DCs with interleukin-10, lipoplysachcharides, and specific antigens. Tolerogenic DCs produced increased amounts of interleukin-10 compared to control DCs. The immune suppressive capacities of tolerogenic DCs were evaluated in a murine model of primary biliary cirrhosis (PBC). This muirne model of PBC was produced by administration of poly I : C, an immune modulator, twice a week. Mice injected with poly I:C developed increased cell infiltration at the portal area and autoantibody in the sera One group of mice received only poly I:C and another two groups of mice received both poly I:C and two administration of either regulatory DCs or PBC antigen-specific regulatory DCs. Mice receiving only poly I:C developed PBC like lesion in the liver, which was down regulated in mice, injected with regulatory DC or antigen-specific regulatory DCs. However, the positivity of autoantibody was not markedly altered due to administration of regulatory DCs. In conclusion, an observational study has been reported in which DC-based therapy maydown regulate inflammatory mucosal milieu of the liver of PBC.
|
